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Abstract: Ziconotide is a conopeptide intrathecal (IT) analgesic which is approved by the 
US Food and Drug Administration (FDA) for the management of severe chronic pain. It is a 
synthetic equivalent of a naturally occurring conopeptide found in the venom of the fish-eating 
marine cone snail and provides analgesia via binding to N-type voltage-sensitive calcium 
channels in the spinal cord. As ziconotide is a peptide, it is expected to be completely degraded 
by endopeptidases and exopeptidases (Phase I hydrolytic enzymes) widely located throughout 
the body, and not by other Phase I biotransformation processes (including the cytochrome P450 
system) or by Phase II conjugation reactions. Thus, IT administration, low plasma ziconotide 
concentrations, and metabolism by ubiquitous peptidases make metabolic interactions of other 
drugs with ziconotide unlikely. Side effects of ziconotide which tend to occur more commonly 
at higher doses may include: nausea, vomiting, confusion, postural hypotension, abnormal gait, 
urinary retention, nystagmus/amblyopia, drowsiness/somnolence (reduced level of conscious-
ness), dizziness or lightheadedness, weakness, visual problems (eg, double vision), elevation of 
serum creatine kinase, or vestibular side effects. Initially, when ziconotide was first administered 
to human subjects, titration schedules were overly aggressive and led to an abundance of adverse 
effects. Subsequently, clinicians have gained appreciation for ziconotide’s relatively narrow 
therapeutic window. With appropriate usage multiple studies have shown ziconotide to be a safe 
and effective intrathecal analgesic alone or in combination with other intrathecal analgesics.
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Introduction
The US Food and Drug Administration (FDA) approved ziconotide (Prialt®; Elan 
Pharmaceuticals, Inc.) on December 28, 2004 for the management of severe chronic 
pain in patients whom intrathecal (IT) therapy is warranted, and who are intoler-
ant of or refractory to other treatments, such as systemic analgesics, adjunctive 
therapies, or IT morphine. Ziconotide is approved for use only in the Medtronic 
SynchroMed® EL, SynchroMed® II Infusion System, and the CADD-Micro® ambula-
tory infusion pump.
Prialt®contains ziconotide acetate, with L-methionine (0.05 mg/mL) and sodium 
chloride as excipients at pH 4.0 to 5.0. Ziconotide is a synthetic equivalent of a natu-
rally occurring conopeptide found in the venom of the fish-eating marine cone snail, 
Conus magnus. This peptide, formerly known as SNX-111 or ω-conotoxin MVIIA, is a 
component of the venom used to immobilize the snail’s prey. Ziconotide is a 25 amino 
acid, polybasic peptide containing 6 cysteine residues linked by 3 disulfide bridges 
with a molecular weight of 2639 Da and a molecular formula of C102H172N36O32S7 .1 Therapeutics and Clinical Risk Management 2009:5 522
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The amino acid sequence and disulfide bridging pattern are 
given below:
Cys-Lys-Gly-Lys-Ala-Lys-Cvs-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cvs-Arg-Ser-Gly-Lys-Cvs-amide 
The three disulfide bridges contribute to stabilization, 
of ziconotide’s well-defined three-dimensional structure,2–4 
which is in part shaped as a cylinder. The cylinder represents 
the amide backbone of ziconotide VIIA overlayed against 
an electrostatic potential surface. Ziconotide is a hydrophilic 
molecule that is freely soluble in water and is practically 
insoluble in methyl t-butyl ether.
Conopeptides
The venoms of the ∼700 species of predatory cone snails 
(genus Conus) are being systematically characterized. Each 
Conus species contains 100 to 200 small, highly structured 
venom peptides (colloquially known as conotoxins or cono-
peptides), which are synthesized and secreted in a venom 
duct.5 Thus, living Conus are likely to express 70,000 
different peptides in their venoms.6
Based on their disulfide connectivity, a highly conserved 
N-terminal precursor sequence and a similar mode of action, 
conotoxins can be classified into 11 superfamilies: A, D, I1, 
I2, J, L, M, O, P, S, and T superfamily.6,7 Each superfamily 
may possess different mechanisms of action and may also 
be divided into several families according to the cysteine 
arrangement.8
Three analgesic targets of analgesic conopeptides 
include: N-type voltage-sensitive calcium channels 
(ω-ziconotide), ω-conotoxin MVIIA also known as N-
methyl-d-aspartate [NMDA] receptors (conantokin-G), and 
neuronal voltage-gated sodium channels (mu-conotoxin 
KIIIA).
Teichert et al reported the discovery and characterization 
of three conantokin peptides from the venom of Conus parius. 
Each peptide (conantokin-Pr1, -Pr2, and -Pr3) contains 19 
amino acids with 3 gamma-carboxyglutamate (Gla) residues, 
a post-translationally modified amino acid characteristic of 
conantokins.9 Electrophysiological assays confirmed that 
conantokins-Pr1, -Pr2, and -Pr3 are N-methyl-d-aspartate 
(NMDA) receptor antagonists, with highest potency for 
NR2B-containing NMDA receptors.9
mu-Conotoxin KIIIA, from Conus kinoshitai, blocks 
mammalian neuronal voltage-gated sodium channels 
(VGSCs) and is a potent analgesic following systemic 
administration in mice.10
Mechanism of action
Ziconotide binds to N-type voltage-sensitive calcium 
channels (NVSCCs) [Cav2.2] located on the primary 
nociceptive (A-δ and C) afferent nerves in the superficial 
layers (Rexed laminae I and II) of the dorsal horn in the spinal 
cord. Ziconotide produces potent antinociceptive effects11 
by selectively binding to N-type voltage sensitive calcium 
channels12,13 on neuronal somata, dendrites, dendritic shafts, 
and axon terminals, thus blocking neurotransmission from 
primary nociceptive afferents.14 Complete chemical synthesis 
of ziconotide was achieved in 1987, and N-type voltage-
sensitive calcium channels (NVSCCs) were subsequently 
identified as its target site.12 It potently inhibits the conduc-
tion of nerve signals (Ki value of 0.5 µM)15 by specifically 
blocking the NVSCC. In the complex with NVSCC, it forms 
a compact folded structure with a binding loop between Cys8 
and Cys15 that also contains Tyr13, an important amino-acid 
residue located at the binding site.16,17
NVSCCs are found exclusively in presynaptic neurons 
where they regulate depolarization-induced calcium influx, 
which subsequently control a variety of calcium-dependent 
processes. NVSCCs are abundantly present in the superficial 
lamina of the spinal-cord dorsal horn, where they have an 
important role in the spinal processing of nociceptive affer-
ent (pain signaling) activity.18,19 The potent inhibition and 
highly selective affinity of ω-conotoxin MVIIA to NVSCC 
(Kd value of 9 pM)20 attracted interest to develop this peptide 
into an antinociceptive agent, since the inhibition of presyn-
aptic NVSCCs results in blocking the release of presynaptic 
algesic neurotransmitters into the synapse.
Ziconotide may also bind to the delta opioid receptor; 
however, its affinity for the δ-opioid receptor is 5 orders of 
magnitude lower than its affinity for NVSCCs.21
Ziconotide preclinical evaluation
Preliminary studies demonstrated that ziconotide has a 
remarkable potent antinociceptive profile in animal models 
with acute, persistent and neuropathic pain after intrathecal 
administration.21 In a rat incisional model of post-operative 
pain, ziconotide demonstrated more potent (ED50 value of 
49 pM) and longer activity than intrathecal morphine (ED50 
value of 2.1 nM).22Therapeutics and Clinical Risk Management 2009:5 523
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Ziconotide displayed no mutagenic or carcinogenic potential 
and no propensity to induce cell proliferation or apoptosis in the 
surrounding CNS tissues. Local toxicity consisted of spinal cord 
compression with associated chronic inflammation attributed 
to pressure exerted by the IT catheter in control and ziconotide 
treated rats and dogs. Dogs treated with IT ziconotide displayed 
no evidence of granuloma formation at the catheter tip,23 as has 
been observed clinically with high-dose IT opioid therapy 24 and 
in a canine IT infusion model at clinically relevant morphine 
doses.25 Ziconotide demonstrated no propensity to interfere with 
cardiac action potentials in vitro, induce QT prolongation in 
vivo, or deplete cardiac catecholamine levels at sympatholytic 
doses in rats.26 Although systemic anaphylaxis was observed in 
guinea pigs, the absence of antibodies to ziconotide in animals 
and human patients indicates that the drug has low immuno-
genic potential.26
Tolerance does not develop to the analgesia induced by 
intrathecal ziconotide in animal experiments and clinical 
trials.27–29 Furthermore, tolerance to morphine antinociception 
did not produce cross-tolerance to ziconotide and the anti-
nociceptive effects of morphine and ziconotide are additive 
and sometimes even synergistic. Ziconotide did not produce 
respiratory depression in response to carbon dioxide.29,30
Nonclinical investigations of ziconotide included a com-
prehensive characterization of its toxicology, incorporating 
acute and subchronic toxicity studies in rats, dogs, and mon-
keys; reproductive toxicity assessments in rats and rabbits; and 
mutagenic, carcinogenic evaluations performed in vivo and in 
vitro.26 Additional investigations assessed the potential for car-
diotoxicity (rats) and immunogenicity (mice, rats, and guinea 
pigs), and the presence or absence of intraspinal granuloma 
formation and local cell proliferation and apoptosis (dogs).26
Pharmacokinetics
The mean cerebrospinal fluid (CSF) volume of distribution 
for ziconotide is about 140 mL (range of 99.2–155 mL) after 
IT administration approximates the estimated total human 
CSF volume.31 Median CSF clearance (CL) of ziconotide 
(0.38 mL/min) approximates the adult human CSF turnover 
rate, providing evidence that the primary mechanism for 
ziconotide CL is bulk CFS flow, rather than a metabolic pro-
cess. The median elimination half-life of IT ziconotide from 
CSF in humans is roughly 4.6 hours (range of 2.9–6.5 hours) 
and protein binding is approximately 50%.31 Although values 
are variable and dose dependent, following a 1 hour infusion 
of a 1 to 10 µg dose, the area under the concentration-time 
curve (AUC) [a measure of total drug exposure that can be 
calculated (as the sum of trapezoids)] is in the range of 83.6 to 
608 ng⋅h/mL and the peak drug concentration (Cmax) is in the 
range of 16.4 to 132 ng/mL.31
IT ziconotide is transported into the systemic circulation, 
where it may become bound to plasma proteins or degraded 
by proteolytic enzymes (the half-life of ziconotide in serum is 
1.3 hours).32 Although formal pharmacokinetic (PK) drug–drug 
interaction studies have not been conducted with ziconotide, 
PK drug interactions are unlikely, due to ziconotide’s low 
protein binding and low plasma concentrations following IT 
administration.32 Coadministration of ziconotide with other drugs 
that act on the CNS may have an additive effect. There is no need 
for dose reduction in response to renal or hepatic failure.32
The time course of ziconotide’s observable pharmacologic 
action appears to develop more slowly than the kinetics of the 
distribution of ziconotide into the CSF. The median time to 
onset of the most commonly reported adverse events (AEs) 
ranged from 3 to 9.5 days. However, an approximation to 
steady-state CSF concentration generally is achieved within 
24 hours (approximately five half-lives). In the Rauck et al 
study of 2006, dose changes could be made two to three times 
per week and no more frequently than every 24 hours. The rela-
tively slow onset of AEs suggests that increments in the dosing 
of ziconotide be made no more frequently than weekly.33
The apparent lag between CSF pharmacokinetics and 
the pharmacodynamics of ziconotide may reflect the drug’s 
slow penetration into the CNS parenchyma. Consistent with 
ziconotide’s molecular weight of approximately 2500 Da 
and its polycationic nature, microdialysis studies in rat brain 
with radioiodinated ziconotide have shown that no detectable 
ziconotide diffused more than 1 mm from the dialysis probe 
in 2 hours of perfusion.34 The slow diffusion of ziconotide in 
neural tissue may also explain the slower-than-expected time 
course of resolution of AEs with discontinuation of ziconotide 
therapy. As stated above, based on the 4.6-hour CSF half-
life of the drug, pharmacologically active concentrations of 
ziconotide would be expected to be cleared within 24 hours.
The CSF PK of ziconotide have been studied after 
1-hour IT infusions of 1 to 10 µg of ziconotide to patients 
with chronic pain.  31 Following one-hour IT administra-
tion of 1 to 10 µg of ziconotide, both total exposure (AUC; 
range: 83.6–608 ng⋅h/mL) and peak exposure (Cmax; range: 
16.4–132 ng/mL) values in the CSF were variable and dose-
dependent, but appeared approximately dose-proportional.31 
During 5 or 6 days of continuous IT infusions of ziconotide at 
infusion rates ranging from 0.1 to 7.0 µg/hour in patients with 
chronic pain, plasma ziconotide levels could not be quanti-
fied in 56% of patients using an assay with a lower limit of 
detection of approximately 0.04 ng/mL.31 Predictably, patients Therapeutics and Clinical Risk Management 2009:5 524
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requiring higher IT infusion dose rates were more likely to 
have quantifiable ziconotide levels in plasma.
Distribution
Ziconotide has a mean CSF volume of distribution (Vd) 
following IT administration that approximates the estimated 
total CSF volume (140 mL), and is roughly 50% bound to 
plasma proteins.35
Metabolism
Ziconotide is cleaved by endopeptidases and exopeptidases at 
multiple sites on the peptide.35 Some ziconotide will leave the 
CSF and gain access into the systemic circulation, where it 
would be susceptible to proteolytic cleavage by various ubiq-
uitous peptidases/proteases present in most organs. It appears 
that ziconotide is readily degraded to peptide fragments 
and their individual constituent free amino acids in vivo. 
Peptide fragments resulting from proteolytic degradation of 
ziconotide have not been evaluated for biologic activity.
elimination
Minimal amounts of ziconotide (1%) were recovered in 
the urine following intravenous ziconotide infustion.35 The 
terminal half-life of ziconotide in CSF after IT administra-
tion was about 4.6 hours (range 2.9–6.5 hours). Mean CSF 
clearance (CL) of ziconotide approximates adult human CSF 
turnover rate (0.3–0.4 mL/min).35
Drug interactions
Formal PK drug–drug interaction studies have not been 
performed with ziconotide.35 As ziconotide is a peptide, it is 
expected to be completely degraded by endopeptidases and 
exopeptidases (Phase I hydrolytic enzymes) widely located 
throughout the body, and not by other Phase I biotransforma-
tion processes (including the cytochrome P450 system) or by 
Phase II conjugation reactions.35 IT ziconotide administration 
results in low plasma ziconotide concentrations, and metabo-
lism by ubiquitous peptidases make metabolic interactions of 
other drugs with ziconotide unlikely. Also, since ziconotide is 
not highly bound in plasma (approximately 50%) and is present 
only low plasma levels following IT administration, clinically 
relevant plasma protein displacement reactions involving 
ziconotide and co-administered medications are unlikely.35
interaction with opioids
Ziconotide does not bind to the mu opioid receptor and its 
pharmacological effects are not blocked by opioid antagonists.35 
In animal models, IT ziconotide potentiated opioid-induced 
reduction in gastrointestinal (GI) motility, but did not potentiate 
morphine-induced respiratory depression.35 It may be conceiv-
able that certain neurotransmitters released from voltage-sensitive 
calcium channels contribute to normal GI motility. In rats receiv-
ing IT ziconotide, additive analgesic effects were observed with 
concurrent administration of morphine, baclofen, or clonidine.35 
Concurrent administration of IT ziconotide and morphine did not 
prevent the development of morphine tolerance in rats.35
interaction with CNS depressants
Of the 1254 patients treated, most received several concomi-
tant systemic medications, including antidepressants (66%), 
anxiolytics (52%), antiepileptic drugs (47%), neuroleptics 
(46%), and sedatives (34%).35 The use of systemic CNS 
depressants concomitant with IT ziconotide may be associ-
ated with an increased incidence of CNS adverse events such 
as dizziness and confusion.35
Administration
Ziconotide should be administered IT (not intravenously) by 
or under the direction of a physician experienced in the tech-
nique of IT administration and who is familiar with the drug 
and device labeling. Ziconotide is intended for IT delivery 
using a programmable implanted variable-rate microinfusion 
device or an external microinfusion device and catheter.35
Ziconotide is supplied as a 25 µg/mL solution in a 
single-use 20 mL glass vial and as a 100 µg/mL solution in 
single-use glass vials containing 1 mL, 2 mL, or 5 mL of 
solution. Ziconotide is used for therapy undiluted (25 µg/mL 
in 20 mL vial) or diluted (100 µg/mL in 1, 2, or 5 mL vials).35 
Only the undiluted 25 µg/mL formulation should be used 
for ziconotide naïve pump priming. Diluted ziconotide is 
prepared with sterile preservative-free 0.9% sodium chlo-
ride injection USP, using aseptic procedures to the desired 
concentration prior to placement in the microinfusion pump. 
The 100 µg/mL formulation may be administered undiluted 
once an appropriate dose has been established. All ziconotide 
solutions should be refrigerated after preparation and infu-
sion should be started within 24 hours.35 Due to adsorption 
of ziconotide to the titanium of the implanted pump and the 
dilution errors that occur with residual pump volume, despite 
reservoir evacuation, the rinse process helps to insure the 
concentration of the anticipated final pump solution.36 There-
fore, it is very important that you do not initiate ziconotide 
without the appropriate rinse process as suggested by the 
manufacturer.35
Treatment should generally be initiated at a delivery of 
0.001to 0.05 µg/hour and upwards titration should proceed Therapeutics and Clinical Risk Management 2009:5 525
Intrathecal ziconotide for severe, chronic pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
extremely slowly. IT ziconotide should not be initiated at more 
than 2.4 µg/day (0.1 µg/hour). Doses may be titrated upward by 
0.01 to 0.05 µg/hour with a maximum increase of 2.4 µg/day 
(0.1 µg/hour) and at intervals of once per week but absolutely 
no more than 2 to 3 times per week, up to a recommended 
maximum of 19.2 µg/day (0.8 µg/hour) after 3 weeks.35 In 
clinical trials, no rebound or other adverse events were related 
to discontinuation of ziconotide despite the fact that treatment 
was almost always discontinued abruptly.35
The dose of IT ziconotide should be slowly adjusted 
according to the patient’s severity of pain, their response to 
therapy, and the occurrence of adverse events. The effective 
dose of ziconotide for analgesia is variable. The average 
dose level at the end of a 3-week titration period used in the 
slow titration clinical trial was 6.9 µg/day (0.29 µg/hour) 
and the maximum dose was 19.2 µg/day (0.8 µg/hour) on 
Day 21.35
An expert consensus statement, developed after the drug 
was marketed, recommends a starting dose of not more than 
0.5 µg/24 hours (0.02 µg/hour) intrathecally and a slow 
titration schedule with potential interval increases of not 
more than 0.5 µg/24 hours (0.02 µg/hour) intrathecally once 
weekly.36 A slower starting rate and less frequent titration 
schedule may decrease the likelihood of serious adverse 
effects. Faster titration schedules should be considered only 
if there is an urgent need for analgesia and potential benefits 
outweigh risks to patient safety, in instances such as palliative 
care. However, clinicians should be aware that, when starting 
at faster infusion rates, adverse effects may require temporar-
ily withholding the medication, thus delaying pain relief for 
the patient.36 Additionally, clinicians should be aware that 
many of the observed side effects of IT ziconotide cannot be 
prevented by slow titration; however, it is possible that their 
severity and frequency of adverse effects may be minimized 
by extremely slow and careful titration schedules.
Contraindications and adverse 
effects
The safety of IT ziconotide administered as a continuous infu-
sion has been evaluated in 1254 patients participating in acute 
and severe chronic pain trials. The duration of treatment has 
ranged from a one-hour IT infusion to treatment lasting for 
more than 7.5 years.35 The mean duration of treatment was 
193 days with 173 patients (14%) treated for at least 1 year. The 
average final dose was 17.6 µg/day (0.73 µg/hour). The most 
frequently reported adverse events (25%) in the 1254 patients 
(662 patient years) in clinical trials were dizziness, nausea, con-
fusion, headache, somnolence, nystagmus, asthenia, and pain.35 
Significant adverse events are less apt to occur when the drug 
is slowly titrated gradually over 3 weeks or longer.
Possible side effects of ziconotide may include:
•  an allergic reaction,
•  nausea, vomiting, seizures, fever, headache, and/or stiff 
neck (eg, meningitis),
•  a change in mental status (cognitive and neuropsychiatric 
alterations) (extreme tiredness, asthenia, confusion, dis-
orientation or decreased alertness),
•  a change in mood or perception (hallucinations, unusual 
feelings in the mouth),
•  postural hypotension, abnormal gait, urinary retention, 
nystagmus/amblyopia
•  drowsiness/somnolence (reduced level of consciousness),
•  dizziness or lightheadedness, weakness,
•  visual problems (eg, double vision),
•  elevation of serum creatine kinase, or
•  vestibular side effects.
Vestibular side effects may be due to ziconotide block-
ing N-type calcium channels in the granular cell layer of the 
cerebellum.37
Ziconotide is contraindicated in patients with a known 
hypersensitivity to ziconotide or any of its formulation 
components and in patients with any other concomitant 
treatment or medical condition that would render IT admin-
istration hazardous. Contraindications to the use of IT anal-
gesia include: conditions such as the presence of infection 
at the microinfusion injection site, systematic infection 
with bacteremia, uncontrolled bleeding diathesis, and spinal 
canal obstruction that impairs circulation of CSF.
Meningitis and other infections
Meningitis can occur due to inadvertent contamination of 
the microinfusion device and other means such as CSF 
seeding due to hematogenous or direct spread from an 
infected pump pocket or catheter tract despite the use of strict 
aseptic techniques. While meningitis is rare with an internal 
microinfusion device and surgically-implanted catheter, the 
incidence increases substantially with external devices. In the 
1254 patients in ziconotide clinical trials with an exposure of 
662 patient-years, meningitis occurred at 3% (40 cases) in the 
ziconotide group using either internal or external microinfusion 
devices and 1% (1 case) in the placebo group with an exposure 
of only 5 patient-years.35 The risk of meningitis with external 
microinfusion devices and catheters was higher with 93% 
cases (38/41) occurring with external infusion systems.35 
Serious infection or meningitis can occur within 24 hours of a 
breach in sterility such as a disconnected catheter.35Therapeutics and Clinical Risk Management 2009:5 526
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Cognitive and neuropsychiatric 
adverse events
CNS-related adverse events may occur with ziconotide, 
including psychiatric symptoms, cognitive impairment, and 
decreased alertness/unresponsiveness. For the 1254 patients 
treated, the following cognitive adverse event rates were 
reported: confusion (33%), memory impairment (22%), speech 
disorder (14%), aphasia (12%), thinking abnormal (8%), and 
amnesia (1%).35 Cognitive impairment may appear gradually 
after several weeks of treatment. The ziconotide dose should 
be reduced or discontinued if signs or symptoms of cognitive 
impairment develop, however, other contributing causes should 
be entertained or investigated as appropriate. Cognitive effects 
of ziconotide are usually reversible within 2 weeks (3–15 days) 
after cessation of therapy.35 Older persons are at higher risk 
for confusion. In placebo-controlled trials, there was a higher 
incidence of suicide, suicide attempts, and suicide ideations in 
ziconotide-treated patients (N = 3) than in the placebo group 
(N = 1). 35 The incidence was 0.10/patient year for placebo 
patients and 0.27/patient-year for ziconotide patients.35
Acute psychiatric disturbances such as hallucinations 
(12%), paranoid reactions (3%), hostility (2%), delirium (2%), 
psychosis (1%), and manic reactions (0.4%) have been reported 
in patients treated with ziconotide.35 Patients with pretreatment 
psychiatric disorders may be at increased risks of the above 
reactions as well as the potential for IT ziconotide to facilitate 
or worsen depression with the risk of suicide in susceptible 
patients. Patients with pre-existing psychiatric disorders should 
be carefully evaluated before instituting ziconotide infusion 
as some of these patients (especially patients with a history of 
psychosis) may not be well suited for ziconotide therapy.
Reduced level of consciousness
Unresponsiveness has occurred while receiving ziconotide. 
The incidence of unresponsiveness or stupor in clinical 
trials was 2%.35 If reduced levels of consciousness occur, 
ziconotide should be discontinued until the event resolves, 
and other etiologies (eg, meningitis) should be considered 
Patients taking concomitant antiepileptic drugs, neurolep-
tics, sedatives, or diuretics may be at higher risk to develop 
depressed levels of consciousness.35 If altered consciousness 
occurs, other central nervous system (CNS) depressant drugs 
should also be discontinued as clinically appropriate.
Elevation of serum creatine kinase 
(CK-MM)
Forty percent of patients from clinical studies (largely open 
label) had serum creatine kinase (CK) levels above the upper 
limit of normal, and 11% had CK levels that were 3 X 
upper limit of normal (ULN)47 (only the muscle isoentyme 
(MM) was elevated in the cases where CK was fractionated). 
Although the CK elevations may occur at any time during 
therapy, the greatest incidence of CK elevation was during 
the first two months of treatment.35 Elevated CKs were more 
often seen in males, in patients who were being treated with 
anti-depressants or antiepileptics, and in patients treated with 
IT morphine.35 The majority of patients with elevations in 
CK, even for prolonged periods of time, did not experience 
limiting side effects. One case of symptomatic myopathy 
with electromyography findings, and two cases of acute renal 
failure associated with rhabdomyolysis and extreme CK 
elevations (17,000–27,000 IU/L) have been reported.35
Prescribing information from the manufacturer recom-
mends that physicians monitor serum CK in patients under-
going treatment with ziconotide periodically (eg, every other 
week for the first month and monthly as appropriate thereaf-
ter).35 During ziconotide infusions, consideration for reduction 
or discontinuation should be entertained in the setting of new 
neuromuscular symptoms (eg, myalgias, myasthenia, muscle 
cramps, asthenia/fatigue), weakness, persistent increasing CK 
levels, or a reduction in physical activity.
Overdosage
The maximum IT dose of ziconotide administered in clinical 
trials was 912 µg/day which is 892.8 µg/day over the maximum 
recommended IT ziconotide dose of 19.2 µg/day.35 At IT doses 
greater than the maximum recommended dose, exaggerated 
pharmacological effects (eg, ataxia, nystagmus, dizziness, stu-
por, unresponsiveness, spinal myoclonus, confusion, sedation, 
hypotension, word-finding difficulties, garbled speech, nausea, 
and vomiting) may be observed, but respiratory depression 
did not occur.35 Overdoses may occur due to pump program-
ming errors or incorrect drug concentration preparations. In 
these cases, patients were observed and ziconotide was either 
temporarily discontinued or permanently withdrawn.35 Most 
patients recovered within 24 hours after ziconotide discontinu-
ation, at which point the ziconotide CSF concentration should 
be less than 5% of peak levels.35
Because ziconotide has no known “antidote”, overdose 
is treated with general medical supportive measures as 
appropriate.35 There have been no reported cases of death 
with ziconotide overdose.35
Clinical experience with ziconotide
In efforts to assess the safety and efficacy of IT ziconotide in 
patients with cancer or AIDS who have refractory pain; Staats Therapeutics and Clinical Risk Management 2009:5 527
Intrathecal ziconotide for severe, chronic pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and colleagues14 performed a double-blind, placebo-controlled, 
randomized trial at 32 study centers in the United States, 
Australia, and the Netherlands. Intrathecal ziconotide was 
titrated over 5 to 6 days, followed by a 5-day maintenance 
phase for responders and crossover of non-responders to the 
opposite treatment group. Mean percentage change in visual 
analog scale of pain intensity (VASPI) score from baseline 
to the end of the initial titration period. Of the population 
evaluated, 67 (98.5%) of 68 patients receiving ziconotide 
and 38 (95%) of 40 patients receiving placebo were taking 
opioids at baseline (median morphine equivalent dosage of 
300 mg/day for the ziconotide group and 600 mg/day for the 
placebo group; P = 0.63, based on mean values), and 36 had 
used intrathecal morphine.14 Mean (SD) VASPI scores were 
73.6 (1.8) mm in the ziconotide group and 77.9 (2.3) mm in the 
placebo group (P = 0.18). Mean VASPI scores improved 53.1% 
(95% confidence interval [CI], 44.0%–62.2%) in the ziconotide 
group and 18.1% (95% CI, 4.8%–31.4%) in the placebo group 
(P  0.001), with no loss of efficacy of ziconotide in the main-
tenance phase.14 Pain relief was moderate to complete in 52.9% 
of patients in the ziconotide group compared with 17.5% in the 
placebo group (P  0.001). Five patients receiving ziconotide 
achieved complete pain relief, and 50.0% of patients receiving 
ziconotide responded to therapy compared with 17.5% of those 
receiving placebo (P = 0.001).14 Intrathecal ziconotide provided 
clinically and statistically significant analgesia in patients 
with pain from cancer or AIDS.14 Compared with placebo, 
ziconotide was associated with a number of (typically dose-
related) adverse events: abnormal gait, dizziness, nystagmus, 
confusion, somnolence, fever, postural hypotension, urinary 
retention, nausea, and vomiting.14
Patients (169 ziconotide, 86 placebo) with severe chronic 
nonmalignant pain unresponsive to conventional therapy and a 
VASPI score 50 mm were treated over a 6-day period in an 
inpatient hospital setting.38 Initial starting dose was 0.4 µg/hour 
and was titrated to analgesia or intolerance (maximum dose 
7.0 µg/hour). The starting and maximum doses were reduced 
to 0.1 µg/hour and 2.4 µg/hour, respectively, due to AEs.38
The mean percentage reduction in VASPI score from 
baseline was 31.2% and 6.0% for ziconotide- and placebo-
treated patients, respectively (P  0.001).38 During the 
initial titration phase, a significantly greater percentage of 
patients in the ziconotide group compared to the placebo 
group reported AEs, including abnormal gait, amblyopia, 
dizziness, nausea, nystagmus, pain, urinary retention, and 
vomiting.38
The most commonly reported SAEs among ziconotide-
treated patients were dizziness (8 occurrences), confusion (6), 
urinary retention (4), nausea and/or vomiting (4), amblyopia 
or visual abnormalities (3), abnormal gait (3), stupor or som-
nolence (3), ataxia or vestibular disorders (3), and encepha-
lopathy (2).38 Other nervous system SAEs reported included 
single cases of agitation, catatonic reaction, thinking abnormal, 
depression, and aphasia.38
The neurocognitive AEs, such as confusion, disorien-
tation, memory impairment, speech difficulties, impaired 
concentration, mental slowing, or thought abnormalities, 
are the most troublesome of the ziconotide-related CNS AEs 
and, if not manageable by dose reduction, often required drug 
discontinuation.38
There was a considerable incidence of ziconotide-associated 
AEs in the 2006 study of Wallace and colleagues38 due to the 
rapid titration and high doses administered.38 The narrow 
therapeutic window of IT ziconotide dictates a slower and more 
cautious titration, which subsequently became incorporated in 
the US product labeling.38
In an attempt to reduce side effects and increase toler-
ability, Rauck et al33 conducted a double-blind, placebo-
controlled study using a slower titration schedule and lower 
maximum dose than previous studies in 220 patients with 
chronic, noncancer refractory to conventional treatment.
Patients randomized to ziconotide (n = 112) or placebo 
(n = 108) started IT infusion at 0.1 mg/hour (2.4 mg/day), 
increasing gradually (0.05–0.1 mg/hour increments) over 
3 weeks. The ziconotide mean dose at termination was 
0.29 mg/hour (6.96 mg/day). Patients’ baseline VASPI 
score was 80.7 (SD 15). Statistical significance was noted 
for VASPI mean percentage improvement, baseline to 
Week 3 (ziconotide [14.7%] vs placebo [7.2%; P = 0.036]) 
and many of the secondary efficacy outcomes measures. 
Significant AEs reported in the ziconotide group were dizzi-
ness, confusion, ataxia, abnormal gait, and memory impair-
ment. Discontinuation rates for AEs and serious AEs were 
comparable for both groups. Slow titration of ziconotide, 
a nonopioid analgesic, to a low maximum dose resulted in 
significant improvement in pain and was better tolerated than 
in two previous controlled trials that used a faster titration to 
a higher mean dose. However, compared with the two previ-
ous studies14,38 the current study had a higher incidence of 
AEs related to higher cortical functions, such as confusion 
and memory impairment.
Such differences could be attributable to the longer dura-
tion of the current study and the higher cumulative dose over 
three weeks compared to only 5 to 6 days in the two previ-
ous controlled trials. However, results from the MMSE in 
the current study indicated no substantial changes in mental Therapeutics and Clinical Risk Management 2009:5 528
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status and no significant differences between the ziconotide 
and placebo groups.
However, no occurrences of respiratory depression, drug 
dependence, or withdrawal symptoms (potential hazards 
of opioid administration) were reported during this study, 
and there was no evidence of tolerance to ziconotide or 
of granuloma formation at the tip of the IT catheter (as is 
observed rarely during IT opioid treatment in association 
with neurological sequelae).
Overall, the results of this study suggest that IT ziconotide 
infusion therapy is an option for patients with severe, refrac-
tory chronic pain. Efficacy data from this study should be 
interpreted with caution, as there was no comparator group 
in the study. An important limitation of this study is that 
it is unlikely that rare AEs would have been detected. The 
detection of such AEs typically requires patient exposure 
well beyond that achieved in this study.39 Additionally, it 
has been suggested that open-label trials are not ideal for 
detecting and assessing the risk for rare AEs because of 
lack of a control group and the potential for under-reporting 
of treatment-emergent AEs.39 Thus far, AEs that have been 
commonly associated with ziconotide are generally not 
life-threatening and typically resolve upon discontinuation 
of therapy. In the case of a serious AE, ziconotide therapy 
can be abruptly interrupted or discontinued without concern 
regarding withdrawal effects.
Wallace et al conducted an open-label, multicenter study 
of patients with severe chronic pain who were followed after 
being initiated on intrathecal ziconotide infusions.40 Efficacy 
assessments included the Visual Analog Scale of Pain Intensity 
and Safety was assessed via adverse events (AEs), vital signs, 
and routine laboratory values. One-hundred and nineteen 
patients received ziconotide for 360 days; total exposure was 
350.9 patient years. Median duration of ziconotide therapy was 
67.5 days (range, 1.2–1215.5 days); mean dose at last infusion 
was 8.4 µg/day (range, 0.048–240.0 µg/day). Median VASPI 
scores at baseline, month 1, and the last available observation 
up to month 2 were 76 mm (range, 4–100 mm), 68 mm (range, 
0–100 mm), and 73 mm (range, 0–100 mm), respectively. 
Most patients (99.7%) experienced 1 AE. Most AEs were 
of mild (43.5%) or moderate (42.3%) severity; 58.6% of AEs 
were considered unrelated to ziconotide. The most commonly 
reported AEs (25% of patients) included nausea, dizziness, 
headache, confusion, pain, somnolence, and memory impair-
ment. Clinically significant abnormalities (3 times the upper 
limit of normal) in creatine kinase levels were reported in 0.9% 
of patients at baseline, 5.7% at month 1, and 3.4% at ziconotide 
discontinuation. No drug-related deaths, IT granulomas, or 
permanent adverse sequelae occurred with ziconotide therapy. 
Wallace et al concluded that IT ziconotide infusions are an 
option for patients with severe, refractory chronic pain.40
Webster et al performed an open-label multicenter study 
evaluating the safety and efficacy of intrathecal ziconotide 
infusions and included 78 patients with chronic pain who had 
completed one of two previous ziconotide clinical trials.41 
Each patient’s initial ziconotide dose was based on his or her 
dose from the study of origin and was adjusted as necessary on 
the basis of adverse events and analgesic effect. The median 
ziconotide dose was 6.48 µg/day (range, 0.00–120.00 µg/day) 
at the initial visit and ranged from 5.52 to 7.20 µg/day across 
all study visits. The most commonly reported new adverse 
events that were considered ziconotide related were memory 
impairment (11.3%); dizziness, nystagmus, and speech 
disorder (8.5% each); nervousness and somnolence (7.0% 
each); and abnormal gait (5.6%). There was no evidence 
of increased adverse event incidence at higher cumulative 
ziconotide doses. Elevations in creatine kinase were noted, 
but the proportion of patients with creatine kinase elevations 
did not change from the initial visit to the termination visit 
(4.1%each). Stable mean VASPI scores during the three 
years of the study suggested no evidence of increased pain 
intensity with increased duration of ziconotide exposure. 
Intrathecal ziconotide infusions appeared to be well tolerated 
and effectively maintained on a longer basis in patients whose 
response to ziconotide and ability to tolerate the drug had been 
previously demonstrated in the short-term.41
New AEs were reported in 91.0% of patients (71 of 78). 
A new severe AE was reported for 70.4% of these patients 
(50 of 71) at some time during the study. Thirty-seven of 
the 71 patients who experienced new AEs (52.1%) reported 
at least one new AE that was considered ziconotide related. 
Eight of the 1044 new AEs reported during the study were 
considered to be both severe and related to ziconotide (ie, 
memory impairment, abnormal gait, chills, hostility, quad-
riplegia, and sweating increased). The most commonly 
reported new AEs that were considered by the investigators 
to be related to ziconotide include: abnormal gait (5.6%), 
dizziness (8.5%), memory impairment (11.3%), nervousness 
(7.0%), nystagmus (8.5%), somnolence (7.0%), and speech 
disorder (8.5%). The incidence of reported new AEs was 
greater in younger patients (ie, 60 years; 97.9%, [46 of 47]) 
than in older patients (ie, 60 years; 80.6%, [25 of 31]).41
The most commonly (1% of patients) reported new 
serious adverse effects include: dehydration (11.4%), lung 
disorder (14.3%), pneumonia (17.1%), and sepsis (14.3%).41 
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leading to interruption or termination of ziconotide therapy 
include: quadriplegia, dry mouth, abdominal pain, infection, 
medication error, hypotension libido decrease, memory 
impairment (all 1.4%), psychosis (2.7%), catheter complica-
tions (4.1%), and pump complications (2.7%).41
Headache, insomnia, and nervousness were more 
common while patients were receiving 4.800 µg/day of 
ziconotide (difference 5 patients); accidental injury, back 
pain, fungal infection, and hypokalemia were more common 
while patients were receiving 4.800 µg/day of ziconotide 
(difference 5 patients). There was no evidence of increased 
AE incidence at higher cumulative ziconotide doses.
Ziconotide exposure totaled 133.4 patient-years during 
this study41 and 339.2 patient-years when cumulative experi-
ence across this study of Webster et al 200841 as well as the 
studies of origin were included.
In the 2000 and 2003 Polyanalgesic Consensus Confer-
ence guidelines,24,42 ziconotide was not assigned to a line 
in the treatment algorithm of intrathecal analgesics for 
pain relief because of limited experience with the drug and 
because of pending FDA review. However, in 2007, the 
Polyanalgesic Consensus Conference panel of experts based 
on relevant new literature and clinical experience decided 
that ziconotide should be “upgraded” to a “first-line IT 
analgesic”43 (see Table 1).
Combinations of ziconotide 
and opioids
To assess the safety and efficacy of adding intrathecal mor-
phine to intrathecal ziconotide in patients treated with stable 
ziconotide doses; Webster et al conducted a multicenter, 
open-label study with a 4-week morphine titration phase 
during which ziconotide was held constant and an exten-
sion phase during which dosing of either drug could vary; 
in twenty-five patients with suboptimal pain relief receiving 
stable ziconotide doses ( 4.8 mcg/day) in one of two ongo-
ing ziconotide trials.44 Ziconotide dosing remained constant 
during the titration phase; intrathecal morphine titration 
was based on each patient’s daily systemic opioid dose at 
the study’s start. During the extension phase, intrathecal 
ziconotide and morphine dosing were adjusted per investi-
gator discretion.
Safety was assessed primarily via adverse events. 
Efficacy was analyzed via percentage change on the visual 
analog scale of pain intensity and in weekly systemic 
opioid consumption. Twenty-five patients enrolled. The 
most common (10% of patients in either study phase) 
study drug-related (ie, ziconotide/morphine combination 
[or ziconotide monotherapy in the extension phase only]) 
treatment-emergent adverse events (TEAEs) included diz-
ziness, peripheral edema, pruritus, and nausea. The median 
IT morphine dose was 0.25 mg/day at the initial visit and 
progressively increased during the titration phase, with 
median values of 0.25, 0.50, 1.00, and 1.25 mg/day at weeks 
1, 2, 3, and 4, respectively. During the extension phase, the 
median IT morphine dose was 1.50 mg/day at week 8 and 
fluctuated from a high of 2.1 mg/day at week 56 to a low 
of 0 mg/day for each of the two patients who completed a 
week 72 visit. During the titration phase, two patients (8.0%) 
reported 6 serious TEAEs, including accidental injury, ataxia, 
confusion, dehydration, subdural hematoma, and urinary 
tract infection, none of which were considered related to 
the study drug.
From the initial visit to week 4, visual analog scale of 
pain intensity scores improved by a mean of 26.3% (95% 
CI, 15.6%–37.1%) but varied during the extension phase 
(mean percentage change from the initial visit ranged 
from −0.4% at week 16 to −35.0% at week 72). Thus, analy-
sis of the primary efficacy variable showed a mean 26.3% 
reduction in VASPI score from the initial visit to week 4, 
and a supportive efficacy analysis using LOCF corroborated 
these findings. Reductions in pain intensity were seen as 
early as week 1 and progressively increased at weeks 2 
and 3 as upward titration of IT morphine continued. As the 
majority of the patients in the study had previously received 
IT opioid therapy, it is unlikely that IT morphine was solely 
responsible for the VASPI score reductions noted during the 
study; VASPI score reductions were more likely attribut-
able to IT ziconotide/morphine combination therapy. Mean 
percentage decrease in systemic opioid consumption from 
the initial visit was 49.1% at week 4 and 51.2% at week 56 
of the extension phase. Webster and colleagues concluded 
that intrathecal morphine, combined with stable intrathecal 
ziconotide doses, reduced pain in patients with previously 
suboptimal pain relief on ziconotide monotherapy.44
Wallace et al also performed a study to assess the safety 
and efficacy of adding intrathecal ziconotide to intrathecal 
morphine in patients being treated with a stable intrathe-
cal morphine dose.45 Wallace and colleagues conducted a 
phase II, multicenter, open-label study with a 5-week titra-
tion phase and an extension phase, enrolling 26 patients with 
suboptimal pain relief receiving stable intrathecal morphine 
doses (2–20 mg/day). Intrathecal morphine dosing remained 
constant during the titration phase. Ziconotide therapy began at 
0.60 µg/day and was titrated to a maximum of 7.2 µg/day. Dur-
ing the extension phase, ziconotide and intrathecal morphine Therapeutics and Clinical Risk Management 2009:5 530
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dosing were adjusted at the investigator’s discretion.45 In their 
study, treatment-emergent adverse events were generally mild 
or moderate; the most common (15% of patients in either 
study phase) study drug-related (ie, ziconotide/morphine 
combination [or ziconotide monotherapy in the extension 
phase only]) events were confusion, dizziness, abnormal gait, 
hallucinations, and anxiety.45 The mean percentage improve-
ment in visual analog scale of pain intensity scores was 14.5% 
(95% CI, −9.4% to 38.5%) from baseline to week 5 and varied 
during the extension phase (range: −0.4%–42.8%). Mean 
percentage change from baseline in systemic opioid consump-
tion was −14.3% at week 5 and varied considerably during the 
extension phase.45
During the titration phase, 2 of 26 patients (7.7%) reported 
3 serious TEAEs, including cellulitis, cerebral ischemia, and 
stupor, none of which were considered related to the study 
drug. Cellulitis was considered related to intercurrent illness, 
whereas cerebral ischemia and stupor had unknown etiolo-
gies. During the extension phase, 4 of 18 patients (22.2%) 
reported 9 serious TEAEs, including confusion, delusions, 
hallucinations, paranoid reaction (3 events in 3 patients), 
pneumonia, psychosis, and syncope. Most of these events 
(6/9, 66.7%) were considered unrelated to the study drug. 
The event of confusion was considered related to pneumonia; 
psychosis and one event of paranoid reaction were considered 
related to intercurrent illness; and one event of paranoid 
reaction, pneumonia, and syncope had unknown etiologies. 
One patient experienced delusions, hallucinations, and one 
episode of paranoid reaction that was considered related to 
the study drug.
When using combination IT therapy, drug stability is 
important to consider. The pump refill schedule used in 
the present study was developed based on the results of 
a simulated pump stability study. In this stability study, 
admixtures of 25 µg/mL ziconotide and 35 mg/mL mor-
phine had an approximately 21% decline in ziconotide 
concentration in 17 days.46 These results suggest that, during 
the refill intervals used in the present study (1 week for the 
titration phase and every 2–3 weeks during the extension 
phase), ziconotide concentrations in patients’ pumps could 
decline considerably. However, stability and its correlation 
to efficacy were not specifically investigated in the simu-
lated pump stability study or in the present study. Further 
studies of ziconotide in combination with other opioids 
are warranted to investigate stability and its correlation 
with efficacy.
Results from studies in animal models have sug-
gested that ziconotide and morphine may have additive 
or synergistic effects. In one study, additive analgesic 
effects of ziconotide and morphine were demonstrated 
Table 1 Recommended algorithm for intrathecal polyanalgesic therapies, 2007
(a) ↔ (b) ↔ (c)
Line #1 (a) morphine, (b) hydromorphone, (c) ziconotide
(d) ↔ (e) ↔ (f)
Line #2: (d) fentanyl, (e) morphine/hyromorphone + ziconotide,  (f) morphine/hydromorphone + bupivacaine/clonidine
(g) ↔ (h)
Line #3: (g) clonidine, (h) morphine/hydromorphone/fentanyl bupivacaine +clonidine + ziconotide
(i) ↔ (j)
Line #4*: (i) sufentanil, (j) sufentanil + bupivacaine +/clonidine + ziconotide 
(k)
Line #5: (k) ropivacaine, buprenorphine, midazolam meperidine, ketorolac
(l)
Line #6: Experimental drugs (l) gabapentin, octreotide, conopeptide, neostigmine, adenosine,
XeN2174, AM336, XeN, ZGX 160
Notes: Line 1: Morphine (a) and ziconotide (c) are approved by the US Food and Drug   Administration for intrathecal analgesic use and are recommended for first-line therapy 
for nociceptive, mixed, and neuropathic pain. Hydromorphone (b) is recommended based on clinical widespread usage and apparent safety.
Line 2: Because of its apparent granuloma-sparing effect and because of its wide apparent use and identified safety, fentanyl (d) has been upgraded to a line 2 agent by the 
consensus conference when the use of the more hydrophilic agents of line 1 (a,b) result in intractable supraspinal side-effects. Combinations of opioid + ziconotide (e) or 
opioid + bupivacaine or clonidine (f) are recommended for mixed and neuropathic pain and may be used interchangeably. When admixing opioids with ziconotide, attention 
must be made to the guidelines for admixing ziconotide with other agents.
Line 3: Clonidine (g) alone or opioids such as morphine/hydromorphone/fentanyl with bupivacaine and/or clonidine mixed with ziconotide (h) may be used when agents in 
line 2 fail to provide analgesia or side-effects occur when these agents are used.
Line 4: Because of its proven safety in animals and humans and because of its apparent granuloma-sparing effects, sufentanil alone (i) or mixed with bupivacaine and/or clonidine 
plus ziconotide (j) is recommended in this line.   The addition of clonidine, bupivacaine, and or ziconotide is to be used in patients with mixed or neuropathic pain. *In patients 
with end of life, the panelists felt that midazolam and octreotide should be tried when all other agents in lines 1–4 have failed.
Line 5: These agents (k), although not experimental, have little information about them in the literature and use is recommended with caution and obvious informed consent 
regarding the paucity of information regarding the safety and efficacy of their use.
Line 6: experimental agents (l) must only be used experimentally and with appropriate independent Review Board (iRB) approved protocols.32Therapeutics and Clinical Risk Management 2009:5 531
Intrathecal ziconotide for severe, chronic pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
with the formalin-induced tonic flinch test; paw pressure, 
hot plate, and tail immersion tests suggested synergistic 
effects of ziconotide and morphine.28 Animal model stud-
ies of the safety of combination ziconotide and morphine 
therapy have been limited to assessments of respiration and 
gastrointestinal motility in rats and mice administered IT 
ziconotide in combination with subcutaneous morphine47 
and assessments of blood pressure changes in rats admin-
istered a combination of IT morphine and ziconotide.48 
These evaluations suggested that IT ziconotide combined 
with subcutaneous morphine does not induce respiratory 
depression and does not increase the susceptibility of 
morphine-tolerant animals to the respiratory depressant 
effects of morphine.47 However, IT ziconotide does appear 
to potentiate morphine-induced inhibition of gastrointes-
tinal motility47 and to enhance the hypotensive effects of 
morphine.48
The drug combination was useful in multiple chronic 
pain conditions, including neuropathic pain, mixed pain, and 
nociceptive pain. Reduced pain intensity was noted as early 
as week 2 of combination therapy and, by week 5, the mean 
decrease in VASPI score was 14.5% in this small group of 
patients with highly refractory severe chronic pain. Wallace 
and colleagues concluded that ziconotide, combined with 
stable intrathecal morphine, may reduce pain and decrease 
systemic opioid use in patients with pain inadequately con-
trolled by intrathecal morphine alone; however, they pointed 
out that clearly, larger, randomized studies with increased 
duration of follow-up and additional quality of life measures 
are warranted to investigate the combination of IT ziconotide 
and IT morphine.45
IT ziconotide added to baclofen therapy
Five of seven patients (71.4%) had IT ziconotide added 
to baclofen therapy, for chronic pain.49 The mean age was 
50.2 years, and the mean baseline VASPI score was 91 mm. 
All five patients had chronic spasticity and neuropathic pain 
(mean pain duration, 8.8 years) and had experienced at least 
one previous failed IT treatment regimen.49
The mean dose of ziconotide was 1.7 µg/day at initiation 
and 4.2 µg/day at last assessment.49 Titration of ziconotide 
was based on patient response to treatment, and titration 
details are included in the patient summaries. The mean 
duration of treatment with ziconotide was approximately 8 
months (median duration, 6 months; range, 2–16 months). 
Intrathecal baclofen was stabilized at a mean dose of 266 
mcg/day.49 All patients were taking at least 1 systemic 
opioid during treatment with the study drugs.49
Analysis of the primary efficacy measure revealed that 
VASPI scores improved by a mean of 50.2% from baseline 
to last assessment.49 The mean time to onset pain relief was 
15 weeks (range, 7–29 weeks) with a corresponding mean 
ziconotide dose of 3.7 mcg/day (range, 1.3–8.1 µg/day). 
One patient (patient 1) reported AEs (nausea and vomiting 
with dehydration) during treatment with ziconotide, but the 
AEs were considered unrelated to ziconotide therapy.49
The remaining two patients were receiving ziconotide 
treatment when baclofen was initiated. Pain intensity 
scores improved by 75% and 30%, respectively. Pain 
relief was evident at two weeks and one week, with corre-
sponding ziconotide doses of 2.4 µg/day and 14.4 µg/day, 
respectively.49
Studies have shown that baclofen is relatively stable 
when combined with either morphine (90% stable for 
30 days) or clonidine (90% stable for 14 weeks).50,51 
On the other hand, the stability of ziconotide tends to be 
compromised when ziconotide is combined with other 
agents.45,52,53 In an experiment investigating the stability of 
admixtures containing ziconotide and baclofen, ziconotide 
maintained 90% stability for 12 days when combined with 
a commercially available baclofen solution and for 20 days 
when combined with powdered baclofen; baclofen con-
centrations were only minimally affected under the same 
conditions.54
“intrathecal cocktails”
Mixtures or combinations of multiple IT analgesic agents are 
even less well studied than single agents; however, various 
combinations continue to be utilized in clinical practice and 
were recognized by the 2007 polyanalgesic consensus confer-
ence which reviewed the safety, compatibility, and efficacy 
data available for various admixtures.43,55
The rationale for IT combination therapy is to combine 
drugs with different mechanisms of action so that afferent 
pain signals are interrupted at several different sites, thus 
producing additive or synergistic pain control. This combined 
effect may also allow for dose reduction of each individual 
drug, which may reduce drug intolerance.
Ziconotide at concentrations of less than 1 mcg/mL is 
not as stable but is very stable at higher concentrations. 
Morphine and hydromorphone may facilitate ziconotide deg-
radation, thus the 2007 polyanalgesic consensus conference 
suggestions limiting the concentration and dose of opioid 
when utilizing opioid/ziconotide admixtures.56 Clonidine 
2 µg/mL combined with ziconotide is stable (roughly 
90% stable to 60 days) whereas bupivacaine/ziconotide is Therapeutics and Clinical Risk Management 2009:5 532
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somewhat less stable.52,53 Ziconotide/baclofen admixtures are 
80% stable over 30 days (and even more stable when com-
pounded with powdered baclofen).54 A ziconotide/clonidine/
morphine admixture was 70% stable for 20 days.53
Ziconotide’s clinical niche
Intrathecal ziconotide infusion therapy appears to be a 
valuable treatment option for moderate to severe pain. 
Despite being a broad-spectrum analgesic, it seems to be 
particularly effective in providing pain relief for severe 
intractable neuropathic pain states,57–59 complex regional 
pain syndromes,59,60 and perhaps certain intractable visceral 
pain states. Its therapeutic niche is still evolving; however, 
it seems to be especially well suited to be utilized in patients 
who may not be ideal candidates for opioid therapy. These 
patient groups may include: patients with active substance 
abuse issues, patients who are highly sensitive to opioid 
adverse effects, patients with obstructive sleep apnea, and 
patients with significant lung disease and/or reduced pul-
monary reserve.
Summary
Ziconotide is a conopeptide intrathecal analgesic which is 
FDA-approved for the management of severe chronic pain. It 
is a synthetic equivalent of a naturally occurring conopeptide 
found in the venom of the fish-eating marine cone snail and 
provides analgesia via binding to N-type voltage-sensitive 
calcium channels in the spinal cord.
Ziconotide appears to be potentially beneficial to some 
patients with intractable pain, but has a narrow therapeu-
tic index. Excessive starting doses initially utilized in 
early clinical studies performed in the 1990s consistently 
produced severe dizziness, memory loss, nystagmus, 
confusion, loss of the ability to word find, and even 
frank psychosis.36 Twelve separate multicenter studies of 
ziconotide, involving over 1200 patients, spanning more 
than 10 years, have demonstrated no permanent sequelae of 
the drug, despite several known instances of inadvertent and 
profound overdosing.36 Multiple studies have shown that 
used appropriately, ziconotide can be a safe and effective 
intrathecal analgesic alone or in combination with other 
intrathecal analgesics. Ziconotide’s clinical niche is still 
evolving but it may be a useful addition to the pharmaco-
logic armamentarium of intrathecal analgesics. Its efficacy 
as monotherapy, as well as its safe and effective combina-
tion with other intrathecal analgesics seem to outweigh its 
disadvantaged such as its narrow therapeutic window and 
potentially adverse effects,
It is imperative that the health care provider prescribing 
ziconotide be familiar with its pharmacology as well as the 
use of other intrathecal analgesics. The use of a “start low 
and go slow” approach to dosing/titration of ziconotide 
remains prudent.
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